Cambrex Increases API Capacity in US, Europe

June 5, 2017
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-06-08-2017, Volume 12, Issue 6

Cambrex announces expansions of its North Carolina API pilot plant and Kalskoga, Sweden large-scale manufacturing facility.

Cambrex Corporation, a manufacturer of small molecule innovator and generic APIs, announced facility expansions in the United States and Europe.

On May 16, 2017, the company reported a $2.4 million investment to expand pilot plant capabilities at its High Point, NC facility, increasing the site's reactor capacity by 30%. The new 400-sq.-ft. suite-the site’s fourth reactor suite-will feature two 2000-L reactors and a 0.6-sq-meter Hastelloy filter dryer and is expected to be operational by early 2018.

In a second investment at the High Point site, the company plans to upgrade its analytical chromatography data systems for quality control and analytical R&D to Empower 3 software (Waters). in Q3 and Q4 of 2017.

On May 30, 2017, the company announced the expansion of large-scale manufacturing capacity and additional continuous-flow manufacturing capacity for high-purity intermediates at its cGMP facility in Karlskoga, Sweden.

The expansion includes the installation of multi-purpose reactors ranging from 4–12 cu. meters and upgrading of the control room within an existing plant on site. Installation of the new equipment, including a 9-cu. meter hydrogenation reactor, is expected to be completed by Q3 2017.

The company also introduced a dedicated continuous flow production unit, capable of producing multiple metric tons of high-purity intermediates per year.

Source: Cambrex